In the 3 years since residual gadolinium-based contrast agent (GBCA) in the brain was first reported, much has been learned about its accumulation, including the pathway of GBCA entry into the brain, the brain distribution of GBCA and its excretion. Here we review recent progress in understanding the routes of gadolinium deposition in brain structures.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963376 | PMC |
http://dx.doi.org/10.1259/bjr.20170115 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!